(via TheNewswire)

Vancouver, BC – TheNewswire - December 2, 2025 – XR Immersive Technologies Inc. (CSE: VRAI, OTC: FNTTF, FSE: 79W0) (“XR” or the “Company”) is providing a corporate update following the appointment of Shafin Diamond Tejani as Special Advisor, originally announced on October 9, 2025.

Since the appointment, the Company has focused on three core priorities:

(1) completing all outstanding financial filings,

(2) advancing commercialization of its health-related digital twin technology, and

(3) progressing through the British Columbia Securities Commission (BCSC) continuous disclosure review and advancing initiatives to restructure outstanding debt to strengthen the balance sheet.

Financial Filings Completed

XR confirms that the following filings are being submitted today (December 2, 2025):

• 2024 audited annual financial statements
   

• 2024 MDA and related certifications
   

• Q1 2025 interim financial statements and MD
   

• Q2 2025 interim financial statements and MD
   

• Q3 2025 interim financial statements and MD
   

• All accompanying certifications  

With these submissions, the Company has now completed all outstanding financial reporting requirements , representing a major step forward in its regulatory and compliance roadmap.

The Company's complete financial statements and Management Discussion & Analysis ("MD&A") are available on SEDAR+ at www.sedarplus.ca .

Advancing Health IP Commercialization

The Company continues to advance the development and commercialization of its digital twin, immersive simulation, and AI-driven health technologies. XR’s portfolio includes:

DigitalTwinX

A digital twin engine capable of generating real-time digital models of patients, clinical workflows, or medical devices. DigitalTwinX integrates biometric data, environmental sensors, and spatial tracking to support simulation, training, and remote assessment applications.

AI Avatar System for Healthcare Simulation

An AI-enabled avatar interface that models patient behavior, guides simulation scenarios, and supports remote education and monitoring environments.

Haptic & Wearable Sensor Integration

XR’s haptic technology, fingerprint-tracking systems, and wearable modules—originally developed for immersive entertainment—are being adapted for rehabilitation, medical training, and remote physiological monitoring.

Continuous Monitoring & Chronic Care Modules

The Company is evaluating the application of its wearable technology architecture within chronic-care workflows, including glucose trend visualization, gait and mobility tracking, and other biometric monitoring pathways.

Background in Healthcare, Strategic Review & Life Sciences Experience

XR Immersive has maintained a presence in the healthcare and life-sciences sector since 2016. The Company has previously collaborated with the U.S. Food and Drug Administration (FDA) and Bayer Pharmaceuticals on immersive programs supporting public-health education, behavioral-health initiatives, and experiential content for Bayer’s “Leaps by Bayer” platform.

Throughout 2024 and 2025, the Company advanced its strategic review to evaluate how its simulation, haptics, immersive interface design, and AI capabilities could be applied within sectors with more durable long-term demand, including digital health.

Areas explored included:

• digital-twin models for chronic-condition visualization;
   

• 3D diagnostic and biomarker-data visualization;
   

• immersive adherence and patient-education tools;
   

• virtual onboarding for health and wellness programs;
   

• haptic-enabled feedback loops; and
   

• remote-monitoring workflows for chronic-care support. 

These activities included early-stage research connected to CGM-adjacent concepts following the Company’s proposed—but ultimately discontinued—acquisition of CGM-related assets in late 2024. Subsequent exploratory work involving Insu Therapeutics , the University of British Columbia, and BC Diabetes examined conceptual hardware and software pathways involving diabetes-engagement and monitoring environments. All such initiatives remain exploratory.

The Company has also participated in preliminary discussions with various Victory Square Technologies portfolio companies—including Victory Square Health, VSDH, Insu Therapeutics, and Pawsible—regarding potential pilot-scale development. These discussions are exploratory in nature.

Next Steps: Regulatory Progress & Balance Sheet Strengthening

With all financial filings now completed, the Company’s next areas of focus include:

BCSC Continuous Disclosure Review

XR continues to work through the BCSC continuous disclosure review process. Upon completion, the Company intends to proceed with the remaining steps required to lift the Cease Trade Order (CTO) and prepare for the resumption of trading .

Debt Restructuring Initiatives

The Company is advancing initiatives to restructure or eliminate the remaining outstanding debt with the objective of:

• strengthening the balance sheet,
   

• improving financial flexibility, and
   

• supporting long-term operational execution. 

Further updates will be provided as these initiatives progress.

“Our first priority was completing the Company’s outstanding filings,” said Sheri Rempel, CEO of XR Immersive Technologies . “With those now submitted, we shift our focus to advancing the regulatory review process and strengthening the balance sheet, while continuing to move forward with the development of our health-related technologies.”

“XR has made steady progress over the past several weeks,” said Shafin Diamond Tejani, Special Advisor . “The next phase involves completing the remaining regulatory steps, addressing debt, and continuing to build pathways for the Company’s digital twin and immersive health solutions.”

Sheri Rempel Director,

Chief Executive Officer and Chief Financial Officer

XR Immersive Tech Inc.

For more information, please visit: Website: www.xrimmersivetech.com

Contact: Investor Relations XR Immersive Tech Inc.

Email: ir@xrimmersivetech.com

About XR Immersive Technologies

XR Immersive Technologies (CSE: VRAI, OTC: FNTTF, FSE: 79W0) builds and acquires immersive technology companies across gaming, training, education, and healthcare. The Company owns proprietary health-related intellectual property, including digital twin technology that enables real-time simulation, training, and monitoring applications for healthcare and wellness. This unique IP positions XR Immersive at the intersection of immersive experiences and digital health, creating opportunities to support medical training, patient engagement, and next-generation virtual care solutions.

FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is generally identifiable by use of the words “believes,” “may,” “plans,” “will,” “anticipates,” “intends,” “could”, “estimates”, “expects”, “forecasts”, “projects” and similar expressions, and the negative of such expressions. Forward-looking information in this news release may include statements about the expected filing of the Annual Filings. Forwardlooking information is subject to known and unknown risks, uncertainties and other factors that may cause VRAI’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances at the date such statements are made including, without limitations, information based on the current state of the Annual Filings and discussions with the auditors of the Company. Although VRAI has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information, and there is no guarantee the Annual Filings will be made on the timeline currently expected or at all. If the Annual Filings are not filed on time or subject to additional delays, the securities of the Company could be subject to a cease trade order or other actions taken by the securities regulators and/or exchanges. Accordingly, readers should not place undue reliance on forward-looking information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information herein is qualified in its entirety by this cautionary statement, and VRAI disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2025 TheNewswire - All rights reserved.